Viz.ai announced a proposed collaboration with Guardant Health, Inc. aimed at addressing challenges in lung cancer care. The collaboration seeks to help oncologists diagnose lung cancer earlier and make more informed treatment decisions to improve patient outcomes.
The intent of this partnership is to bridge clinical practice gaps in the lung cancer patient journey by facilitating timely biomarker testing with the Guardant360 CDx liquid biopsy. This is expected to accelerate precision diagnosis and optimal treatment selection.
Dr. Chris Mansi, CEO of Viz.ai, stated that this collaboration represents a promising step forward in the fight against lung cancer, leveraging AI and genomics. The Viz.ai One platform, which operates in 1,700 hospitals, will integrate Guardant's insights to identify patients with disease and direct them to appropriate specialists and treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.